EMEA-001719-PIP01-14 - paediatric investigation plan

L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser

Key facts

• Active substance:
  L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser
• Therapeutic area:
  Neurology
• Decision number:
  P/0101/2015
• PIP number:
  EMEA-001719-PIP01-14
• Pharmaceutical form(s):
  Powder for solution for injection
• Condition(s) / indication(s):
  Treatment of sarcoidosis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  08/05/2015
• Compliance check done:
  No

Decision

P/0101/2015: EMA decision of 8 May 2015 on the granting of a product specific waiver for L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (EMEA-001719-PIP01-14)

Reference Number: EMA/211869/2015